Investigational drug shows promise in ovarian cancer
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. Prof. Michael Friedlander from Australia presented the results of an international collaborative trial which administered the drug to 35 patients with recurrent ovarian, fallopian tube or peritoneal carcinoma. At the ESMO Congress, he presented final results of the trial on behalf of his co-investigators.
Women who had already been treated with one or two previous chemotherapy regimens were eligible for the study provided they only had an elevated CA-125 or small tumors on scans. Each participant received 800mg of the oral drug daily, and the primary outcome measure was a decrease in blood levels of the protein CA-125.
CA-125 is a biological marker used to predict tumor recurrence and response to chemotherapy. Levels of the protein rise on average about 3 months before onset of symptoms or scan evidence of recurrence. Hence, it is an attractive marker to assess the efficacy of new agents such as pazopanib when the tumor volume is low.
The study showed that 31% of the patients had a greater than 50% decrease in CA-125 levels, with median duration of response at 113 days, Prof. Friedlander said. It was generally well tolerated, with a similar spectrum of side-effects seen with other angiogenesis inhibitors.
"Many patients with ovarian cancer will have a recurrence of cancer following initial chemotherapy," he said. "This study clearly demonstrates that pazopanib is an active, well-tolerated drug for women with recurrent ovarian cancer."
The findings of this study support further investigation of the potential role of pazopanib in the management of women with ovarian cancer, Prof. Friedlander added. An international phase III study investigating the drug for ovarian cancer will now go ahead.
"The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis," Prof. Friedlander said. "Typically, these patients are managed with surgery followed by combination chemotherapy. Unfortunately most patients will relapse usually within 2 years following the initial therapy. There is therefore a real need to investigate novel agents such as pazopanib to ensure new therapeutic options for patients with ovarian cancer."
Source: European Society for Medical Oncology
Articles on the same topic
- New drug substantially extends survival in pancreatic cancerTue, 16 Sep 2008, 14:44:35 UTC
- European disparities in access to cancer drugsTue, 16 Sep 2008, 14:44:19 UTC
- Study establishes role for gefitinib in Asian nonsmokers with lung cancerTue, 16 Sep 2008, 14:44:17 UTC
- Promising new treatment option for women with recurrent ovarian cancerMon, 15 Sep 2008, 15:17:00 UTC
- Ovarian cancer drug trial reveals promising new treatmentMon, 15 Sep 2008, 14:29:17 UTC
Other sources
- New Drug Substantially Extends Survival In Pancreatic Cancerfrom Science DailyWed, 17 Sep 2008, 19:14:24 UTC
- Investigational drug shows promise in ovarian cancerfrom Biology News NetWed, 17 Sep 2008, 12:14:41 UTC
- New ovarian cancer treatment is developedfrom UPITue, 16 Sep 2008, 19:07:12 UTC
- New drug substantially extends survival in pancreatic cancerfrom PhysorgTue, 16 Sep 2008, 14:43:28 UTC
- Investigational drug shows promise in ovarian cancerfrom Biology News NetMon, 15 Sep 2008, 22:21:58 UTC
- Hope, confusion in hunt for ovarian cancer testsfrom PhysorgMon, 15 Sep 2008, 20:28:33 UTC
- Hope, confusion in hunt for ovarian cancer testsfrom AP HealthMon, 15 Sep 2008, 19:42:56 UTC
- Investigational drug shows promise in ovarian cancerfrom PhysorgMon, 15 Sep 2008, 15:14:57 UTC
- Ovarian Cancer Drug Trial Reveals Promising New Treatmentfrom Science DailyMon, 15 Sep 2008, 14:28:18 UTC
- Investigational Drug Shows Promise In Ovarian Cancerfrom Science DailyMon, 15 Sep 2008, 14:28:12 UTC